Ruxolitinib: a targeted treatment option for patients with polycythemia vera
Kris Vaddi,1 Srdan Verstovsek,2 Jean-Jacques Kiladjian3 1Drug Discovery, Incyte Corporation, Wilmington, DE, 2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Clinical Investigations Center, Hôpital Saint-Louis et Université Paris Did...
Guardado en:
Autores principales: | Vaddi K, Verstovsek S, Kiladjian JJ |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e9b74c39000f4fbfa80a712811c8f25f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Polycythemia Vera (PV): Update on Emerging Treatment Options
por: Benevolo G, et al.
Publicado: (2021) -
CONCOMITANT LATENT POLYCYTHEMIA VERA AND MGUS.
por: Fidan KHALILOVA, et al.
Publicado: (2021) -
Exploring redox vulnerabilities in JAK2V617F-positive cellular models
por: Keli Lima, et al.
Publicado: (2021) -
Ruxolitinib as an emerging treatment in myelofibrosis
por: Emanuel RM, et al.
Publicado: (2013) -
A CASE OF POLYCYTHEMIA DIAGNOSED AS HEMOGLOBIN ANDREW-MINNEAPOLIS
por: Mustafa Bilici, et al.
Publicado: (2021)